New drug duo aims to wipe out lung tumors before surgery

This study tests whether adding the experimental drug rilapentib alpha to standard chemotherapy can shrink tumors more effectively before surgery in people with stage II-III non-small cell lung cancer. Participants will receive the drug combination for four cycles, then undergo surgery, followed by a year of maintenance therapy. The goal is to see if this approach leads to a complete disappearance of cancer cells in the removed tissue and improves long-term survival.